We exist to provide better treatment options WA patients with bloods cancers through increasing access to clinical trials.

Clinical trials are the most important tool we have for improving the survival of patients with cancer. You should discuss with your doctor whether a clinical trial is available and appropriate for you.

GB5121-2101: STAR-CNS

GB5121-2101: STAR-CNS The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum…
Read More

EZH-302

EZH-302 A Phase 1b/3 Double Blind Randomized, Active-Controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma DiseaseRelapsed/Refractory Follicular…
Read More

ESCALADE

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)
Read More

COALITION

A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with…
Read More

LOXO-BTK-20022

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously…
Read More

BGB-16673-101

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients…
Read More

GCT3013-02

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in…
Read More

STARGLO

STARGLO Starglo is a phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and…
Read More

CRSP-ONC-001

This is an open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX110 in subjects…
Read More

DREAMM 8

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in…
Read More

FRONTMIND

A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide…
Read More

Epcoritamab

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in…
Read More

BRUIN MCL-321

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with…
Read More

64264681LYM1002

A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633…
Read More

D8230C00002

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in…
Read More

AMLM25

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly Acute…
Read More

75348780LYM1001

A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in…
Read More

IGM-2323

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in…
Read More

ENHANCE

A Randomized, Double Blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine plus Placebo in…
Read More

NHL33

NHL33 An ALLG Window Study of Acalabrutinib plus Rituximab followed by Cytarabine, Oxaliplatin, Dexamethasone and Rutixumab (R-DHAOx) + Autologous Stem Cell Transplant (ASCT) in newly diagnosed fit Mantle Cell Lymphoma…
Read More

DREAMM 3

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin…
Read More

AMLM22/D2

The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to…
Read More

ITHACA

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone…
Read More

GCT-3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Read More

MALT-1

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of…
Read More

GO29781

An open-label, multicenter, phase I/IB trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as…
Read More

FORMA

A Phase 1/2 study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of FT-2102 with or without azacitidine…
Read More

GMI-1271-301

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy…
Read More

CC-90007-CP-004

A Phase 1, 2-Part, Multicenter, Open-label, 3-Arm Study to Determine the Effect of Enasidenib (CC-90007) on the…
Read More

DREAMM6

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide…
Read More

LOXO-BTK-18001

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma…
Read More

LEVERAGE

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment Naïve Follicular Lymphoma
Read More

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature…
Read More

Clinical Trial FAQ’s

Menu